California, USA-based drugmaker Valeant Pharmaceuticals says that problems with its distribution chain and weak US sales of Zelapar (selegiline HCl) and Kinerase (N6-furfuryladenine) were key to its poor third-quarter performance. The firm swung into a $12.0 million loss for the period ended September 30, 2007, in stark contrast to the $13.7 million profit it recorded in the comparable three months last year.
Total revenue for the quarter was down 1% to $208.6 million, short of the consensus forecast of $229.5 million that emerged from a Thomson Financial analyst survey. The contribution from Valeant's alliance with Roche, which covers the antiviral ribavirin, declined 33% to $14.1 million, due to increased competition in Europe and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze